

## SAFETY DATA SHEET

### SECTION 1 : IDENTIFICATION

**Product Name:** Lidocaine Hydrochloride Injection, USP  
**Manufacturer Name:** Fresenius Kabi USA, LLC  
**Address:** Three Corporate Drive  
 Lake Zurich, Illinois 60047  
**General Phone Number:** (847) 550-2300  
**Customer Service Phone Number:** (888) 386-1300  
**Health Issues Information:** (800) 551-7176  
**SDS Creation Date:** January 08, 2009  
**SDS Revision Date:** June 01, 2015  
**(M)SDS Format:**

### SECTION 2 : HAZARD(S) IDENTIFICATION

GHS Pictograms:



**Signal Word:** DANGER.

**GHS Class:** Respiratory sensitisation. Category 1.  
 Skin Sensitization. Category 1.  
 Reproductive toxicity. Effects on or via lactation.

**Hazard Statements:** May cause allergy or asthma symptoms or breathing difficulties if inhaled.  
 May cause an allergic skin reaction.  
 May cause harm to breast-fed children.

**Precautionary Statements:** Obtain special instructions before use.  
 Do not breathe dust/fume/gas/mist/vapours/spray.  
 Avoid breathing dust/fume/gas/mist/vapours/spray.  
 Avoid contact during pregnancy and while nursing.  
 Wash hands thoroughly after handling.  
 Do not eat, drink or smoke when using this product.  
 Contaminated work clothing should not be allowed out of the workplace.  
 Wear protective gloves/protective clothing/eye protection/face protection.  
 In case of inadequate ventilation wear respiratory protection.  
**IF ON SKIN:** Wash with plenty of water.  
**IF INHALED:** Remove victim to fresh air and keep at rest in a position comfortable for breathing.  
**IF exposed or concerned:** Get medical advice/attention.  
 Specific treatment (see ... on this label).  
 If skin irritation or rash occurs: Get medical advice/attention.  
 If experiencing respiratory symptoms: Call a POISON CENTER or doctor/physician.  
 Take off contaminated clothing and wash it before reuse.  
 Dispose of contents/container in accordance with Local, State, Federal and Provincial regulations.

**Emergency Overview:** This product is intended for therapeutic use only when prescribed by a physician. Potential adverse reactions from prescribed doses and overdoses are described in the package insert.

**Route of Exposure:** Inhalation Ingestion Eye contact Skin Absorption. Injection.

**Potential Health Effects:**

**Eye:** Contact with eyes may cause irritation.

**Signs/Symptoms:** Adverse reactions from therapeutic doses are generally dose related and may result from high plasma levels caused by excessive dosage, rapid absorption, or inadvertent intravascular injection. The most commonly reported adverse events are excitatory and/or depressant for the central nervous system and cardiovascular system. Allergic reactions are usually cutaneous lesions, urticaria, edema, or anaphylactoid reactions. Occupational exposure has not been fully investigated.

**Aggravation of Pre-Existing Conditions:** Individuals with a known history of hypersensitivity to local anesthetics of the amide type, individuals with STOKES-ADAMS syndrome, Wolff-Parkinson-White syndrome, or severe degrees of sinoatrial, atrioventricular, or intraventricular block.

### SECTION 3 : COMPOSITION/INFORMATION ON INGREDIENTS

Chemical Name	CAS#	Ingredient Percent	EC Num.
Lidocaine Hydrochloride	137-58-6	10 mg/mL or 20 mg/mL	
Methylparaben	99-76-3	0.1 %	
Sodium Chloride	7647-14-5	7 mg/mL or 6 mg/mL	
Water for Injection	7732-18-5	Quantity Sufficient	

**Note:** Product Code 20805 is preservative-free. Product Codes 920102, 20110, and 20202 contain methylparaben as a preservative.

## SECTION 4 : FIRST AID MEASURES

<b>Eye Contact:</b>	Immediately flush eyes with plenty of water for at least 15 to 20 minutes. Ensure adequate flushing of the eyes by separating the eyelids with fingers. Get immediate medical attention.
<b>Skin Contact:</b>	Immediately wash skin with plenty of soap and water for 15 to 20 minutes, while removing contaminated clothing and shoes. Get medical attention if irritation develops or persists.
<b>Inhalation:</b>	If inhaled, remove to fresh air. If not breathing, give artificial respiration or give oxygen by trained personnel. Seek immediate medical attention.
<b>Ingestion:</b>	If conscious, flush mouth out with water immediately. Call a physician or poison control center immediately. Do not induce vomiting unless directed to do so by medical personnel. Never give anything by mouth to an unconscious person.
<b>Other First Aid:</b>	For Adverse Event Information, please call (800) 551-7176.

## SECTION 5 : FIRE FIGHTING MEASURES

<b>Flash Point:</b>	Not established.
<b>Flash Point Method:</b>	Not established.
<b>Auto Ignition Temperature:</b>	Not established.
<b>Lower Flammable/Explosive Limit:</b>	Not established.
<b>Upper Flammable/Explosive Limit:</b>	Not established.
<b>Fire Fighting Instructions:</b>	Evacuate area of unprotected personnel. Use cold water spray to cool fire exposed containers to minimize risk of rupture. Do not enter confined fire space without full protective gear. If possible, contain fire run-off water.
<b>Extinguishing Media:</b>	Use alcohol resistant foam, carbon dioxide, dry chemical, or water fog or spray when fighting fires involving this material. Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
<b>Protective Equipment:</b>	As in any fire, wear Self-Contained Breathing Apparatus (SCBA), MSHA/NIOSH (approved or equivalent) and full protective gear.
<b>Hazardous Combustion Byproducts:</b>	Thermal decomposition products may include smoke and toxic fumes. Oxides of carbon, oxides of nitrogen and other organic substances may be formed. Other undetermined low molecular weight hydrocarbon compounds may be released in small quantities depending upon specific conditions of combustion.

## SECTION 6 : ACCIDENTAL RELEASE MEASURES

<b>Personnel Precautions:</b>	Evacuate area and keep unnecessary and unprotected personnel from entering the spill area. Avoid personal contact and breathing vapors or mists. Use proper personal protective equipment as listed in Section 8.
<b>Environmental Precautions:</b>	Avoid runoff into storm sewers, ditches, and waterways.
<b>Methods for containment:</b>	Contain spills with an inert absorbent material such as soil, sand or oil dry.
<b>Methods for cleanup:</b>	Absorb spill with inert material (e.g., dry sand or earth), then place in a chemical waste container. After removal, flush spill area with soap and water to remove trace residue.

## SECTION 7 : HANDLING and STORAGE

<b>Handling:</b>	When handling pharmaceutical products, avoid all contact and inhalation of vapor, mists and/or fumes. Use with adequate ventilation. Use only in accordance with directions.
<b>Storage:</b>	Store at controlled room temperature 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature].
<b>Work Practices:</b>	Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower.
<b>Hygiene Practices:</b>	Wash thoroughly after handling. Avoid contact with eyes and skin. Avoid inhaling vapor or mist.

## SECTION 8: EXPOSURE CONTROLS, PERSONAL PROTECTION

<b>Engineering Controls:</b>	General ventilation is sufficient if this product is being used in a controlled medical setting (clinic, hospital, medical office) for its sole intended parenteral (injection) purpose. Otherwise, use appropriate engineering control such as process enclosures, local exhaust ventilation, or other engineering controls including use of a biosafety cabinet / fume hood to control airborne levels below recommended exposure limits.
<b>Eye/Face Protection:</b>	Chemical splash goggles. Wear a face shield also when splash hazard exist.
<b>Skin Protection Description:</b>	Protective laboratory coat, apron, or disposable garment recommended.
<b>Hand Protection Description:</b>	Wear appropriate protective gloves. Consult glove manufacturer's data for permeability data. Nitrile rubber or natural rubber gloves are recommended.

**Respiratory Protection:** No personal respiratory protective equipment is normally required when this product is being used/administered by a licensed healthcare practitioner (i.e. an end-user such as a clinician / doctor / nurse) for its sole intended parenteral (injection) purpose in a controlled medical setting. The need for respiratory protection will vary according to the airborne concentrations and environmental conditions. A NIOSH approved air-purifying respirator with an organic vapor cartridge or canister may be permissible under certain circumstances. Consult the NIOSH web site (<http://www.cdc.gov/niosh/npptl/topics/respirators/>) for a list of respirator types and approved suppliers.

**Other Protective:** Consult with local procedures for selection, training, inspection and maintenance of the personal protective equipment.

#### EXPOSURE GUIDELINES

### SECTION 9 : PHYSICAL and CHEMICAL PROPERTIES

**Physical State:** Liquid solution.

**Boiling Point:** Not established.

**Melting Point:** Not established.

**Solubility:** Soluble. in water.

**Vapor Density:** Not established.

**Vapor Pressure:** Not established.

**Percent Volatile:** Not established.

**pH:** 5.0-7.0

**Molecular Formula:** Mixture

**Molecular Weight:** 288.82

**Flash Point:** Not established.

**Flash Point Method:** Not established.

**Auto Ignition Temperature:** Not established.

### SECTION 10 : STABILITY and REACTIVITY

**Chemical Stability:** Stable under normal temperatures and pressures.

**Hazardous Polymerization:** Not reported.

**Incompatible Materials:** Avoid acids and bases. Avoid contact with oxidizing agents.

### SECTION 11 : TOXICOLOGICAL INFORMATION

**Acute Toxicity:** sert. Adverse reactions from therapeutic doses are generally dose related and may result from high plasma levels caused by excessive dosage, rapid absorption, or inadvertent intravascular injection. The most commonly reported adverse events are excitatory and/or depressant for the central nervous system and cardiovascular system. Allergic reactions are usually cutaneous lesions, urticaria, edema, or anaphylactoid reactions. Occupational exposure has not been fully investigated.

#### Lidocaine Hydrochloride :

**Acute Toxicity:** Acute Toxicity:  
LD50 IV Rat: 21 mg/kg  
LD50 IV Mouse: 15 mg/kg

**Acute Effects:** Adverse reactions from therapeutic doses are generally dose related and may result from high plasma levels caused by excessive dosage, rapid absorption, or inadvertent intravascular injection. The most commonly reported adverse events are excitatory and/or depressant for the central nervous system and cardiovascular system. Allergic reactions are usually cutaneous lesions, urticaria, edema, or anaphylactoid reactions. Occupational exposure has not been fully investigated.

#### Lidocaine Hydrochloride :

**RTECS Number:** AN7525000

**Ingestion:** Oral - Rat LD50: 317 mg/kg [Details of toxic effects not reported other than lethal dose value]  
Oral - Mouse LD50: 220 mg/kg [Behavioral - Convulsions or effect on seizure threshold Behavioral - Rigidity (including catalepsy) Lungs, Thorax, or Respiration - Respiratory stimulation]

**Other Toxicological Information:** Intravenous. - Human TDLo: 23 mg/kg [Behavioral - muscle contraction or spasticity Lungs, Thorax, or Respiration - dyspnea]  
Intravenous. - Mouse LD50: 20 mg/kg [Behavioral - convulsions or effect on seizure threshold Vascular - BP lowering not characterized in autonomic section Lungs, Thorax, or Respiration - other changes]  
Intravenous. - Rabbit LDLo: 41 mg/kg [Details of toxic effects not reported other than lethal dose value]  
Intravenous. - Guinea pig LDLo: 65 mg/kg [Details of toxic effects not reported other than lethal dose value]  
Intravenous. - Mouse LD50: 39.4 mg/kg [Details of toxic effects not reported other than lethal dose value]  
Intravenous. - Rat LD50: 18 mg/kg [Details of toxic effects not reported other than lethal dose value]  
Intravenous. - Rat TDLo: 5 mg/kg [Vascular - BP lowering not characterized in autonomic section]  
Intravenous. - Rat TDLo: 2343 ug/kg/5M [Cardiac - change in rate]  
Intravenous. - Rat TDLo: 4688 ug/kg/5M [Vascular - BP lowering not characterized in autonomic section]  
Intravenous. - Rabbit TDLo: 3 mg/kg [Cardiac - change in rate Cardiac - cardiac output Vascular - BP lowering not characterized in autonomic section]  
Subcutaneous - Rat LD50: 335 mg/kg [Details of toxic effects not reported other than lethal dose value]

Subcutaneous - Mouse LD50: 238 mg/kg [Details of toxic effects not reported other than lethal dose value]  
Subcutaneous - Guinea pig LD50: 120 mg/kg [Details of toxic effects not reported other than lethal dose value]  
Subcutaneous - Human TDLo: 33.3 ug/kg [Behavioral - analgesia]  
Subcutaneous - Mouse TDLo: 50 mg/kg [Peripheral Nerve and Sensation - local anesthetic]  
Subcutaneous - Mouse TDLo: 150 mg/kg [Behavioral - convulsions or effect on seizure threshold]  
Intraperitoneal. - Rat LD50: 133 mg/kg [Behavioral - somnolence (general depressed activity)]  
Behavioral - convulsions or effect on seizure threshold Lungs, Thorax, or Respiration - other changes]  
Intraperitoneal. - Mouse LD50: 102 mg/kg [Peripheral Nerve and Sensation - local anesthetic]  
Behavioral - convulsions or effect on seizure threshold Behavioral - ataxia]  
Intraperitoneal. - Rat TDLo: 2 mg/kg [Blood - other changes]

#### **Methylparaben :**

**RTECS Number:** DH2450000

**Skin:** Administration onto the skin - Rabbit Standard Draize test.: 0.1 mL/24H  
Administration onto the skin - Rabbit Standard Draize test.: 0.5 mL/21D (Intermittent)  
Administration onto the skin - Rat TDLo: 374.92 gm/kg/13W (Intermittent) [Nutritional and Gross Metabolic - Weight loss or decreased weight gain Blood - Other changes]

**Ingestion:** Oral - Mouse LD50: >8 gm/kg [Peripheral Nerve and Sensation - Flaccid paralysis without anesthesia (usually neuromuscular blockage) Behavioral - Ataxia]  
Oral - Mouse LD50: >8000 mg/kg [Behavioral - Ataxia]  
Oral - Rat LD50: 2100 mg/kg [Details of toxic effects not reported other than lethal dose value]

**Other Toxicological Information:** Intravenous. - Mouse TDLo: 100 mg/kg [Vascular - shock Lungs, Thorax, or Respiration - respiratory depression]  
Intravenous. - Mouse TDLo: 2.5 mg/kg [Lungs, Thorax, or Respiration - tumors]  
Subcutaneous - Mouse TDLo: 165 mg/kg [Behavioral - ataxia Lungs, Thorax, or Respiration - respiratory depression]  
Subcutaneous - Mouse LD50: 1.2 gm/kg [Details of toxic effects not reported other than lethal dose value]  
Subcutaneous - Rat LD50: >500 mg/kg [Details of toxic effects not reported other than lethal dose value]  
Subcutaneous - Mouse TDLo: 49.5 mg/kg/3D (intermittent) [Related to Chronic Data - changes in uterine weight]  
Subcutaneous - Mouse TDLo: 165 mg/kg/3D (intermittent) [Reproductive - Maternal Effects - uterus, cervix, vagina Related to Chronic Data - changes in uterine weight]  
Intraperitoneal. - Mouse LD50: 960 mg/kg [Peripheral Nerve and Sensation - flaccid paralysis without anesthesia (usually neuromuscular blockage) Behavioral - somnolence (general depressed activity) Behavioral - ataxia]  
Intraperitoneal. - Mouse LD50: 125 mg/kg [Details of toxic effects not reported other than lethal dose value]  
Intraperitoneal. - Rat LD50: 960 mg/kg [Details of toxic effects not reported other than lethal dose value]

#### **Sodium Chloride :**

**RTECS Number:** VZ4725000

**Eye:** Eye - Rabbit Standard Draize test.: 10 mg [Moderate]

**Skin:** Administration onto the skin - Rabbit LD50: >10 gm/kg [Details of toxic effects not reported other than lethal dose value]  
Administration onto the skin - Rabbit Standard Draize test.: 50 mg/24H [mild]  
Administration onto the skin - Rabbit Standard Draize test.: 500 mg/24H [mild]

**Inhalation:** Inhalation - Rat LC50: >42 gm/m<sup>3</sup>/1H [Details of toxic effects not reported other than lethal dose value]

**Ingestion:** Oral - Mouse LD50: 4 gm/kg [Details of toxic effects not reported other than lethal dose value]  
Oral - Rat LD50: 3000 mg/kg [Details of toxic effects not reported other than lethal dose value]

**Other Toxicological Information:** Intravenous. - Mouse LD50: 645 mg/kg [Details of toxic effects not reported other than lethal dose value]  
Intravenous. - Rabbit LDLo: 1100 mg/kg [Behavioral - convulsions or effect on seizure threshold Behavioral - muscle contraction or spasticity Cardiac - other changes]  
Intravenous. - Guinea pig LDLo: 300 mg/kg [Details of toxic effects not reported other than lethal dose value]  
Intravenous. - Mouse TDLo: 2.1 mg/kg [Vascular - other changes Blood - hemorrhage Skin and Appendages - dermatitis, irritative (after systemic exposure)]  
Intravenous. - Rabbit LDLo: 1.5 mg/kg [Details of toxic effects not reported other than lethal dose value]  
Intravenous. - Rabbit TDLo: 0.04 mg/kg [Vascular - other changes Blood - hemorrhage Skin and Appendages - dermatitis, irritative (after systemic exposure)]  
Subcutaneous - Rat LDLo: 3500 mg/kg [Behavioral - irritability]  
Subcutaneous - Mouse LD50: 3 gm/kg [Details of toxic effects not reported other than lethal dose value]  
Subcutaneous - Guinea pig LDLo: 2160 mg/kg [Details of toxic effects not reported other than lethal dose value]  
Subcutaneous - Rabbit TDLo: 0.04 mg/kg [Vascular - other changes Skin and Appendages - dermatitis, irritative (after systemic exposure)]  
Subcutaneous - Mouse TDLo: 1900 mg/kg [Reproductive - Effects on Embryo or Fetus - fetal death]  
Subcutaneous - Mouse TDLo: 1900 mg/kg [Reproductive - Specific Developmental Abnormalities - musculoskeletal system]  
Subcutaneous - Mouse TDLo: 2500 mg/kg [Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)]  
Subcutaneous - Mouse TDLo: 13440 mg/kg [Reproductive - Fertility - abortion]  
Intraperitoneal. - Mouse LD50: 2602 mg/kg [Details of toxic effects not reported other than lethal dose value]  
Intraperitoneal. - Rat LD50: 2600 mg/kg [Details of toxic effects not reported other than lethal dose value]  
Intraperitoneal. - Rat LDLo: 3.72 gm/kg [Behavioral - tremor Behavioral - convulsions or effect on seizure threshold]  
Intraperitoneal. - Rat TDLo: 1710 mg/kg [Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Effects on Embryo or Fetus - fetal death Reproductive - Specific Developmental Abnormalities - musculoskeletal system]  
Intraperitoneal. - Rat TDLo: 10 gm/kg [Reproductive - Effects on Newborn - behavioral]  
Intraperitoneal. - Rat Cytogenetic analysis: 2338 mg/kg

## **SECTION 12 : ECOLOGICAL INFORMATION**

**Ecotoxicity:** No ecotoxicity data was found for the product.

**Environmental Stability:** No environmental information found for this product.

---

## SECTION 13 : DISPOSAL CONSIDERATIONS

---

**Waste Disposal:** Dispose of in accordance with Local, State, Federal and Provincial regulations.

---

## SECTION 14 : TRANSPORT INFORMATION

---

**DOT Shipping Name:** Not Regulated.

**DOT UN Number:** Not Regulated.

---

## SECTION 15 : REGULATORY INFORMATION

---

### Lidocaine Hydrochloride :

**TSCA Inventory Status:** Listed

**EINECS Number:** 205-302-8

**Canada DSL:** Listed

### Methylparaben :

**TSCA Inventory Status:** Listed

**EINECS Number:** 202-785-7

**Canada DSL:** Listed

### Sodium Chloride :

**TSCA Inventory Status:** Listed

**EINECS Number:** 231-598-3

**Canada DSL:** Listed

### Water for Injection :

**TSCA Inventory Status:** Listed

**Canada DSL:** Listed

---

## SECTION 16 : ADDITIONAL INFORMATION

---

### HMIS Ratings:

**SDS Creation Date:** January 08, 2009

**SDS Revision Date:** June 01, 2015

**SDS Format:**

### Disclaimer:

The information contained herein pertains to this material. It is the responsibility of each individual party to determine for themselves the proper means of handling and using these materials based on their purpose and intended use. Fresenius-Kabi assumes no liability resulting from the use of or reliance upon the information contained in this material safety data sheet. This material safety data sheet does not constitute the guaranty or specifications of the product.

Copyright© 1996-2015 Actio Corporation. All Rights Reserved.